Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA)
A specialty healthcare company developing treatments for rare diseases sought Raremark’s support for an early-stage pediatric trial program testing an investigational medicine in Sanfilippo syndrome. Raremark was commissioned to run a nine-month online campaign to raise the profile of the program and to find and refer up to four of the nine patients needed for the Phase I study in the United States; to a study site that initially had no patients of their own.
We found, prescreened and referred three eligible children and their parents within three weeks of study start-up.
Download the Xperiome case study Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA).
Sign up for updates
If you’re an industry professional and would like to subscribe to updates from our research team, including our research projects and our Rare Opinion blog, fill in your details below and we’ll add you to our mailing list.
Get in touch
Interested in working with us? we’d love to hear from you. Please use the form below to provide us with a few details and we’ll get back in touch with you.